Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC скачать в хорошем качестве

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck speaks to ecancer in an online interview for the virtual ASCO 2020 meeting. He discusses the CheckMate 9LA trial which looks at nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy versus 4 cycles chemo as first-line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC). Prof Reck outlines the background and reasoning for trialling the combination of checkpoint inhibitors, with the addition of 2 cycles of chemo. He gives a detailed description of the positive response for the combination arm, and outlines the toxicities which showed nothing out of the ordinary. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php